News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,173 Results
Type
Article (41305)
Company Profile (286)
Press Release (658582)
Section
Business (208149)
Career Advice (2083)
Deals (35847)
Drug Delivery (90)
Drug Development (81926)
Employer Resources (172)
FDA (16274)
Job Trends (15032)
News (350940)
Policy (33025)
Tag
Academia (2618)
Alliances (50046)
Alzheimer's disease (1245)
Approvals (16203)
Artificial intelligence (133)
Bankruptcy (354)
Best Places to Work (11679)
Biotechnology (202)
Breast cancer (122)
Cancer (1104)
Cardiovascular disease (98)
Career advice (1741)
Cell therapy (241)
Clinical research (65084)
Collaboration (390)
Compensation (200)
COVID-19 (2561)
C-suite (99)
Data (1134)
Diabetes (158)
Diagnostics (6268)
Earnings (86583)
Employer resources (149)
Events (112134)
Executive appointments (316)
FDA (16817)
Funding (357)
Gene therapy (183)
GLP-1 (587)
Government (4416)
Healthcare (18982)
Infectious disease (2647)
Inflammatory bowel disease (108)
Interviews (319)
IPO (16499)
Job creations (3716)
Job search strategy (1492)
Layoffs (420)
Legal (7983)
Lung cancer (179)
Manufacturing (180)
Medical device (13419)
Medtech (13424)
Mergers & acquisitions (19429)
Metabolic disorders (410)
Neuroscience (1523)
NextGen Class of 2024 (6609)
Non-profit (4573)
Northern California (1489)
Obesity (236)
Opinion (185)
Patents (102)
People (57555)
Phase I (20201)
Phase II (28648)
Phase III (21363)
Pipeline (460)
Postmarket research (2640)
Preclinical (8653)
Radiopharmaceuticals (237)
Rare diseases (224)
Real estate (6036)
Regulatory (21915)
Research institute (2375)
Resumes & cover letters (358)
Southern California (1309)
Startups (3619)
United States (13635)
Vaccines (557)
Weight loss (173)
Date
Today (1)
Last 7 days (676)
Last 30 days (3571)
Last 365 days (35984)
2024 (33048)
2023 (40485)
2022 (51675)
2021 (56303)
2020 (54770)
2019 (47460)
2018 (35741)
2017 (32833)
2016 (32300)
2015 (38442)
2014 (32127)
2013 (27105)
2012 (29398)
2011 (30031)
2010 (28126)
Location
Africa (759)
Arizona (196)
Asia (38633)
Australia (6364)
California (3351)
Canada (1296)
China (255)
Colorado (147)
Connecticut (153)
Europe (83936)
Florida (462)
Georgia (116)
Illinois (346)
Indiana (197)
Kansas (97)
Maryland (584)
Massachusetts (2632)
Michigan (162)
Minnesota (276)
New Jersey (964)
New York (969)
North Carolina (737)
Northern California (1489)
Ohio (140)
Pennsylvania (848)
South America (1139)
Southern California (1309)
Texas (467)
Utah (91)
Washington State (363)
700,173 Results for "dyadic international inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.
June 28, 2024
·
4 min read
Business
Dyadic Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial results for the first quarter of 2024 and highlighted recent Company progress.
May 14, 2024
·
21 min read
Business
Dyadic Provides Alternative Proteins Business Update and Announces Attendance at Bioprocess International Conference
September 23, 2024
·
6 min read
Business
Dyadic to Attend Industry Events in April 2024
Dyadic International, Inc. announced that its management will be attending the following industry events during the month of April 2024.
March 27, 2024
·
3 min read
Business
Dyadic to Report First Quarter 2024 Financial Results on Tuesday, May 14, 2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the first quarter 2024 and host a corporate update conference call on Tuesday, May 14, 2024.
April 30, 2024
·
3 min read
Business
Dyadic Reports 2023 Full Year Results and Recent Company Progress
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced its financial result for the year end 2023 and highlighted recent Company progress.
March 28, 2024
·
20 min read
BioMidwest
Dyadic to Attend Industry Events in March 2024
Dyadic International, Inc. announced that its management will be attending the following industry events during the month of March 2024.
March 1, 2024
·
3 min read
Dyadic to Present at BioProcess International
Dyadic International, Inc. today announced that Joseph Hazelton, Chief Business Officer of Dyadic will be presenting at BioProcess International.
September 12, 2023
·
3 min read
Dyadic Announces Publication of C1 Monoclonal Antibody in Nonhuman Primate Study in Nature Communications
Dyadic International, Inc. (“Dyadic” or the “Company”) (NASDAQ: DYAI) today announced the online publication of the manuscript “Filamentous fungus-produced human monoclonal antibody provides protection against SARS-CoV-2 in hamster and nonhuman primate models” in Nature Communications (“Springer-Nature”), an international journal publishing peer-reviewed research in all fields of science and technology.
March 26, 2024
·
5 min read
Business
Dyadic to Report Full Year 2023 Financial Results and Host Conference call on Thursday, March 28, 2024
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI) today announced that it will report its financial results for the year ended 2023 and host a corporate update conference call on Thursday, March 28, 2024.
March 14, 2024
·
3 min read
1 of 70,018
Next